Sensei Biotherapeutics ( (SNSE) ) has shared an announcement.
On March 27, 2025, Sensei Biotherapeutics announced favorable preliminary results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a monoclonal antibody targeting VISTA, in PD-(L)1 resistant tumors. The trial showed an overall response rate nearly three times higher than historical PD-(L)1 rechallenge rates, with notable responses observed in Merkel Cell Carcinoma and MSI-H Colorectal Cancer patients. These findings suggest solnerstotug may offer a significant clinical benefit in select tumor types. The company plans to initiate a Phase 2 study in early 2026, contingent on securing sufficient capital, with ongoing analyses to optimize trial design and patient selection.
More about Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical-stage biotechnology company developing next-generation immunotherapies for cancer. The company utilizes its TMAb™ platform to engineer conditionally active therapeutics aimed at modulating immune responses within the tumor microenvironment.
YTD Price Performance: -16.15%
Average Trading Volume: 333,124
Technical Sentiment Signal: Buy
Current Market Cap: $10.97M
See more insights into SNSE stock on TipRanks’ Stock Analysis page.